pharmaphorum.com
Apr 8, 2025, 18:16
Alectinib approved in Scotland for ALK+ lung cancer post-surgery – ALK Positive Lung Cancer UK
ALK Positive Lung Cancer UK shared a post on LinkedIn:
“Today, the Scottish Medicines Consortium officially announces the approval of Alectinib (Alecensa) for post-surgical treatment of ALK-positive lung cancer in stages IB to IIIA, aimed at preventing the recurrence of cancer.
This approval offers a new treatment option for patients in Scotland within this specific group, significantly improving disease-free survival compared to traditional chemotherapy.
Alectinib is already approved for similar use in England.
Patients now have access to an effective treatment that can notably extend the disease-free period following surgery, improving their quality of life.”
More posts featuring ALK Positive Lung Cancer UK.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 13, 2025, 06:03
Apr 13, 2025, 05:56
Apr 13, 2025, 05:55
Apr 13, 2025, 05:10
Apr 13, 2025, 05:05